Literature DB >> 18690834

Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies.

Alejandra del C Alonso1, Ben Li, Inge Grundke-Iqbal, Khalid Iqbal.   

Abstract

The accumulation of hyperphosphorylated tau is a common feature of several dementias. Tau is one of the brain microtubule-associated proteins. Here we discuss tau's function in microtubule assembly and stabilization and with regards to tau's interactions with other proteins, membranes, and DNA. We describe and analyze important posttranslational modifications: hyperphosphorylation, glycosylation, ubiquitination, glycation, polyamination, nitration, and truncation. We discuss how these post-translational modifications can alter tau's biological function and what is known about tau self-assembly, and we propose a mechanism of tau polymerization. We analyze the impact of natural mutations on tau that cause fronto-temporal dementia associated with chromosome 17 (FTDP-1 7). Finally, we consider whether tau accumulation or its conformational change is related to tau-induced neurodegeneration, and we propose a mechanism of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690834     DOI: 10.2174/156720508785132307

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  43 in total

1.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

Review 2.  [Pathogenesis and prevention of Alzheimer's disease: when and in what way does the pathological process begin?].

Authors:  H Braak; S Feldengut; K Del Tredici
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

3.  Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.

Authors:  Lina Adwan; Gehad M Subaiea; Riyaz Basha; Nasser H Zawia
Journal:  J Neurochem       Date:  2014-10-18       Impact factor: 5.372

Review 4.  Tau-induced neurodegeneration: mechanisms and targets.

Authors:  Cindy Beharry; Leah S Cohen; Jing Di; Kawsar Ibrahim; Susan Briffa-Mirabella; Alejandra del C Alonso
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

5.  Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes.

Authors:  Chris R Guthrie; Brian C Kraemer
Journal:  J Mol Neurosci       Date:  2011-02-22       Impact factor: 3.444

6.  Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.

Authors:  Tomás L Falzone; Shermali Gunawardena; David McCleary; Gerald F Reis; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2010-09-03       Impact factor: 6.150

7.  Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases.

Authors:  Yang Yu; Xiaoqin Run; Zhihou Liang; Yi Li; Fei Liu; Ying Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-01-13       Impact factor: 5.372

8.  "Clicked" sugar-curcumin conjugate: modulator of amyloid-β and tau peptide aggregation at ultralow concentrations.

Authors:  Sukanta Dolai; Wei Shi; Christopher Corbo; Chong Sun; Saadyah Averick; Dinali Obeysekera; Mina Farid; Alejandra Alonso; Probal Banerjee; Krishnaswami Raja
Journal:  ACS Chem Neurosci       Date:  2011-10-13       Impact factor: 4.418

9.  Recent origin and spread of a common Welsh MAPT splice mutation causing frontotemporal lobar degeneration.

Authors:  Roberto Colombo; Daniela Tavian; Matthew C Baker; Anna M T Richardson; Julie S Snowden; David Neary; David M A Mann; Stuart M Pickering-Brown
Journal:  Neurogenetics       Date:  2009-04-14       Impact factor: 2.660

Review 10.  Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer's disease.

Authors:  José-Carlos Fernández-Morales; Juan-Alberto Arranz-Tagarro; Enrique Calvo-Gallardo; Marcos Maroto; Juan-Fernando Padín; Antonio G García
Journal:  ACS Chem Neurosci       Date:  2012-08-29       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.